Skip to content

Mindfulness Meditation for Sleep and Anxiety Post Acquired Brain Injury: Pilot Study

Journal of Studies in Medical Sciences December 25, 2025 DOI: 10.20849/jsms.v1i1.1542 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Pilot study with one-group pretest-posttest design Peer reviewed
Sample size 11
Population Adults with acquired brain injury
Intervention Mindfulness meditation
Duration Eight sessions
Measures Pittsburgh Sleep Quality Index (PSQI), Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form
Topics Anxiety Meditation
Key points The telehealth mindfulness meditation program significantly improved sleep efficiency, overall sleep quality, and anxiety scores in adults with acquired brain injury.

Abstract

Quality sleep is essential for recovery from acquired brain injury (ABI); however, there is limited research in the field that examines sleep within this population. This study aims to investigate the effect of an eight-session telehealth mindfulness meditation program on sleep quality and anxiety in adults with ABI. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), while anxiety was measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form. A one-group pretest-posttest design was employed, involving 11 participants in this pilot study. Most participants were female (81.1%), with a mean age of 30.91 years (± 16.60 years). The results demonstrated significant improvements (p < 0.05) in PSQI sleep efficiency, overall sleep quality, and PROMIS anxiety scores. The telehealth mindfulness meditation program showed promising results and has the potential to be implemented as an intervention to address sleep and anxiety. These preliminary findings support the need for further investigation into sleep and anxiety using mindfulness meditation in this population.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Related reading

Explore topics

Anxiety Meditation